XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

XTX Topco Ltd increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 177.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,773 shares of the biopharmaceutical company’s stock after purchasing an additional 68,245 shares during the quarter. XTX Topco Ltd’s holdings in Amicus Therapeutics were worth $871,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC acquired a new stake in Amicus Therapeutics in the fourth quarter worth about $29,000. Covestor Ltd increased its position in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 2,312 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Amicus Therapeutics in the fourth quarter worth about $59,000. GAMMA Investing LLC increased its position in Amicus Therapeutics by 1,610.8% in the first quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 7,007 shares during the period. Finally, Thrivent Financial for Lutherans acquired a new stake in Amicus Therapeutics in the fourth quarter worth about $104,000.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $6.32 on Monday. The firm has a market capitalization of $1.95 billion, a P/E ratio of -52.66 and a beta of 0.53. Amicus Therapeutics, Inc. has a 1 year low of $5.51 and a 1 year high of $12.65. The business has a 50-day moving average of $6.05 and a 200-day moving average of $7.42. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92.

Analyst Ratings Changes

A number of analysts recently commented on the company. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group decreased their target price on Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, May 2nd. UBS Group boosted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, Wall Street Zen upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.